TPI Receives SFDA Approval for Its Anti-Diabetic Drug Gliclazide

Friday, May 13, 2011 General News
Email Print This Page Comment
Font : A-A+

For more information, please contact:

    James Jiayuan Tong M.D. Ph.D.

    Chief Financial Officer, Chief Business & Development Officer

    Director

    Tianyin Pharmaceutical Co., Inc.

    Web:     http://www.tianyinpharma.com

    Email:   Dr.Tong@tianyinpharma.com

    Tel:     +86-28-8551-6696 (Chengdu, China)

               +86-134-3655-0011 (China)

               +1-949-350-6999 (U.S.)

    Address: 23rd Floor, Unionsun Yangkuo Plaza

             No. 2, Block 3, South Renmin Road

             Chengdu, 610041

             China



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook